Understanding Wegovy dosing: a clear guide

• The recommended Wegovy injection maintenance dose is 2.4 mg once weekly for most uses, with 1.7 mg as an option depending on the indication and tolerability, and 7.2 mg available for some adults using it for weight reduction.
• The 0.25 mg starting dose and the escalation steps over 16 weeks are meant to reduce gastrointestinal side effects.
• Dose delays, adjustments, and restarts depend on tolerability, treatment response, clinical need, and the label's missed-dose instructions.

This article is not individualized medical advice; discuss with your clinician which dose and schedule fit you.

Wegovy (semaglutide) injection is a GLP‑1 receptor agonist approved for several distinct uses in combination with a reduced‑calorie diet and increased physical activity. The injection is indicated to reduce the risk of major adverse cardiovascular events (cardiovascular death, non‑fatal myocardial infarction, or non‑fatal stroke) in adults with established cardiovascular disease and either obesity or overweight. It is also indicated to reduce excess body weight and maintain long‑term weight reduction in adults and pediatric patients aged 12 years and older with obesity, and in adults with overweight and at least one weight‑related comorbid condition. In addition, it holds an accelerated approval for the treatment of noncirrhotic metabolic dysfunction‑associated steatohepatitis (MASH), formerly called NASH, with moderate to advanced liver fibrosis (stages F2 to F3) in adults.

The dosing schedule is identical across all adult and pediatric injection indications: a low starting dose of 0.25 mg once weekly, increased in 4‑week steps to reduce the risk of gastrointestinal adverse reactions. The starting dose and intermediate steps are not intended as therapeutic doses; their purpose is to allow the body to adapt. The goal is to reach an effective maintenance dose that a person can tolerate over the long term.

• Weeks 1 to 4 (initiation): 0.25 mg once weekly.
• Weeks 5 to 8 (step 1): 0.5 mg once weekly.
• Weeks 9 to 12 (step 2): 1.0 mg once weekly.
• Weeks 13 to 16 (step 3): 1.7 mg once weekly.
• Week 17 onward (maintenance): 2.4 mg once weekly (recommended).

Wegovy carries a boxed warning because semaglutide causes thyroid C‑cell tumors in rodents at clinically relevant exposures. It is unknown whether Wegovy causes these tumors, including medullary thyroid carcinoma (MTC), in humans. As a result, Wegovy is contraindicated in anyone with a personal or family history of MTC or with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It is also contraindicated in patients with known hypersensitivity to semaglutide or any of the excipients in the injection or tablets.

The label includes warnings for acute pancreatitis, acute gallbladder disease, hypoglycemia (especially with insulin or insulin secretagogues), acute kidney injury from volume depletion, severe gastrointestinal adverse reactions, hypersensitivity reactions including anaphylaxis and angioedema, diabetic retinopathy complications in patients with type 2 diabetes, heart rate increase, and pulmonary aspiration during general anesthesia or deep sedation. The label also states that the Wegovy FlexTouch pen should never be shared between patients, even if the needle is changed.

Large randomized trials support the cardiovascular and weight‑reduction indications in adults. In the SELECT cardiovascular outcomes trial, adults with established cardiovascular disease and obesity or overweight who took Wegovy injection experienced a statistically significant reduction in the composite endpoint of cardiovascular death, non‑fatal myocardial infarction, or non‑fatal stroke compared with placebo. The weight‑reduction trials STEP 1 through STEP 4 demonstrated placebo‑subtracted weight losses that supported the 1.7 mg and 2.4 mg maintenance doses, and the label notes that the 7.2 mg dose is reserved for adults who have tolerated 2.4 mg for at least 4 weeks and need additional weight reduction.

In the STEP TEENS trial, pediatric patients aged 12 to 17 years with obesity received Wegovy injection once weekly. The label designates 2.4 mg as the recommended maintenance dose and 1.7 mg as an alternative, with selection based on treatment response and tolerability. The MASH indication is supported by a trial of adults with biopsy‑confirmed noncirrhotic MASH and fibrosis stages F2 or F3; the recommended maintenance dose is 2.4 mg once weekly, and the dose can be decreased to 1.7 mg if 2.4 mg is not tolerated. Because the MASH approval is accelerated, continued approval may depend on verification of clinical benefit in a confirmatory trial.

For all approved indications in adults and pediatric patients aged 12 and older, the starting dose of Wegovy injection is 0.25 mg subcutaneously once weekly in weeks 1 through 4. Once-weekly injection doses then increase to 0.5 mg (weeks 5–8), 1 mg (weeks 9–12), and 1.7 mg (weeks 13–16). If a patient does not tolerate an injection dose during escalation, the label states to consider delaying escalation for 4 weeks.

From week 17 onward, the maintenance dose depends on the indication:

• Cardiovascular risk reduction in adults: 2.4 mg (recommended) or 1.7 mg once weekly.
• Weight reduction in adults: 1.7 mg or 2.4 mg (recommended) once weekly; 7.2 mg may be considered only after tolerating 2.4 mg for at least 4 weeks and when more weight reduction is clinically indicated.
• Weight reduction in pediatric patients aged 12 and older: 2.4 mg (recommended) or 1.7 mg once weekly.
• Noncirrhotic MASH with moderate to advanced liver fibrosis in adults: 2.4 mg once weekly; if not tolerated, decrease to 1.7 mg and consider re‑escalation to 2.4 mg.

Treatment response and tolerability should guide the choice of maintenance dose. People with diabetes should have blood glucose monitored before starting and during treatment because of the hypoglycemia risk with concomitant insulin or insulin‑secretagogue therapy.

The label distinguishes between missing one dose and missing two or more. If one injection is missed and the next scheduled dose is more than 2 days away, administer the missed dose as soon as possible. If the next scheduled dose is less than 2 days away, skip the missed dose and resume dosing on the regularly scheduled day. After two or more consecutive missed injection doses, the label instructs reinitiating the dose escalation from a lower dose to reduce the risk of gastrointestinal adverse reactions. Ask your prescriber which dose to restart at.

Wegovy tablets are a different formulation with a once‑daily oral schedule and are only indicated for adults. The tablet starting dose is 1.5 mg once daily, escalating every 30 days to a maintenance dose of 25 mg once daily. This article covers the injection only. Concomitant use of Wegovy tablets or injection with any other semaglutide‑containing product or any other GLP‑1 receptor agonist is not recommended.

• Whether the 1.7 mg, 2.4 mg, or (only for adults on weight reduction) 7.2 mg maintenance dose is appropriate for your indication, tolerability, and response.
• Any step‑up dose that causes nausea, vomiting, diarrhea, or other gastrointestinal symptoms so you can decide together whether to delay the next escalation by 4 weeks.
• If you have type 2 diabetes, how to adjust insulin or insulin secretagogue doses before and during Wegovy treatment to reduce hypoglycemia risk.
• What to do if you miss one dose or more than two consecutive doses, and which lower dose to restart with.
• Any history of medullary thyroid carcinoma or MEN 2 in your family, or past pancreatitis, gallbladder disease, severe gastroparesis, or diabetic retinopathy.
• If you are pregnant, planning pregnancy, or breastfeeding: Wegovy may cause fetal harm, and for weight‑reduction or cardiovascular risk‑reduction patients the label says to discontinue Wegovy when pregnancy is recognized. For weight reduction, cardiovascular risk reduction, or MASH when the potential risk outweighs the potential benefit, the label says to discontinue Wegovy at least 2 months before a planned pregnancy because of semaglutide's long half‑life. Breastfeeding is not recommended during tablet treatment, and the same caution applies to the injection.

What is the starting dose of Wegovy?

0.25 mg once weekly for the first four weeks. This is a tolerance-building step, not a maintenance dose.

How long does it take to reach the full maintenance dose?

Approximately 16 weeks, with a dose increase every four weeks.

Can I speed up the dose escalation if I feel fine?

No, not without explicit guidance from your prescriber.

What happens if I miss an injection?

See the missed-dose section above. Take it if your next dose is more than 48 hours away, and skip it if less than 48 hours away. After two or more consecutive missed doses, the label calls for restarting dose escalation at a lower dose, so check with your prescriber before the next injection.

Where do I inject Wegovy?

Into the fatty tissue just under the skin of the abdomen, thigh, or upper arm. Rotate sites. Do not inject into muscle or a vein.

What is the 7.2 mg dose and who is it for?

A higher maintenance dose for adults using Wegovy for weight reduction who have tolerated 2.4 mg for at least 4 weeks and need additional weight reduction. Ask your prescriber and pharmacist about current availability.

Can I take Wegovy if I have liver disease?

Wegovy is approved for a specific liver condition (noncirrhotic MASH with F2 to F3 fibrosis), but it is not approved to treat MASH with cirrhosis. Discuss your full liver health history with your clinician.

Can Wegovy be used with other GLP-1 drugs?

No. It should not be combined with other semaglutide products or other GLP-1 receptor agonists.

Is Wegovy approved for use in teenagers?

Yes, for weight reduction. Wegovy injection is approved to reduce excess body weight and maintain weight reduction long term in adolescents aged 12 years and older with obesity. Its safety and effectiveness have not been established in pediatric patients for cardiovascular risk reduction, at the 7.2 mg dose, in children younger than 12, or for MASH, and Wegovy tablets have not been established in pediatric patients. Bring this question directly to a pediatric specialist or endocrinologist.

What should I do if I cannot tolerate a dose step?

Contact your prescriber. Dose escalation can be delayed. This is an accepted approach.